文献速递泌尿男性生殖肿瘤

晚期尿路上皮癌中游离肿瘤DNA与肿瘤组织的二代测序一致性初步评估

Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance.
PubMed 文献 · Ann Oncol · 2017-01-01

该初步分析纳入22例转移性尿路肿瘤患者,比较配对肿瘤组织(FoundationOne)与游离肿瘤DNA(Guardant360)的二代测序结果。两种检测平台总体一致性仅16.4%,同期检测亚组为17.1%,而两次ctDNA检测间接受系统治疗的亚组平均一致性为55.5%。研究表明临床可用NGS panel在晚期尿路上皮癌中存在显著不一致。

要点

  • 肿瘤组织与ctDNA的NGS总体一致性仅16.4%(范围0%-50%)。
  • 同期检测的6例患者一致性为17.1%(范围0%-50%)。
  • 两次ctDNA检测间接受系统治疗的5例患者平均一致性为55.5%。

核心结论

  • 研究提示晚期尿路上皮癌中临床可用NGS panel之间存在显著不一致,即使检测采集时间相近。
  • 需要更好地理解这两种可能互补的NGS平台,以更好地整合入临床实践。

研究设计与样本

  • 初步分析纳入22例转移性尿路肿瘤患者,具备配对肿瘤组织(FoundationOne)和游离肿瘤DNA(Guardant360)的NGS数据。

主要发现

  • 从IV期诊断到首次基因组检测的中位时间为23.5天(0-767天),既往晚期疾病系统治疗中位线数为0(0-3)。
  • 最常见基因组改变位于TP53(50.0%)、TERT启动子(36.3%)、ARID1(29.5%)、FGFR2/3(20.5%)、PIK3CA(20.5%)和ERBB2(18.2%)。
  • 两种检测平台总体一致性仅16.4%(0%-50%),同期检测的6例患者(中位间隔36天)一致性为17.1%(0%-50%)。
  • 两次ctDNA检测间接受中位1线系统治疗的5例患者,平均一致性为55.5%(12.1%-100.0%)。
  • 肿瘤组织突变负荷与G360报告中基因组改变数量(P < 0.001)、已知基因组改变数量(P = 0.009)、F1报告中意义未明变异数量(P < 0.001)及F1报告中基因组改变总数(非VUS和VUS)(P < 0.001)显著相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advances in cancer genome sequencing have led to the development of various next-generation sequencing (NGS) platforms. There is paucity of data regarding concordance of different NGS tests carried out in the same patient. METHODS: Here, we report a pilot analysis of 22 patients with metastatic urinary tract cancer and available NGS data from paired tumor tissue [FoundationOne (F1)] and cell-free circulating tumor DNA (ctDNA) [Guardant360 (G360)]. RESULTS: The median time between the diagnosis of stage IV disease and the first genomic test was 23.5 days (0-767), after a median number of 0 (0-3) prior systemic lines of treatment of advanced disease. Most frequent genomic alterations (GA) were found in the genes TP53 (50.0%), TERT promoter (36.3%); ARID1 (29.5%); FGFR2/3 (20.5%), PIK3CA (20.5%) and ERBB2 (18.2%). While we identified GA in both tests, the overall concordance between the two platforms was only 16.4% (0%-50%), and 17.1% (0%-50%) for those patients (n = 6) with both tests conducted around the same time (median difference = 36 days). On the contrary, in the subgroup of patients (n = 5) with repeated NGS in ctDNA after a median of 1 systemic therapy between the two tests, average concordance was 55.5% (12.1%-100.0%). Tumor tissue mutational burden was significantly associated with number of GA in G360 report (P < 0.001), number of known GA (P = 0.009) and number of variants of unknown significance (VUS) in F1 report (P < 0.001), and with total number of GA (non-VUS and VUS) in F1 report (P < 0.001). CONCLUSIONS: This study suggests a significant discordance between clinically available NGS panels in advanced urothelial cancer, even when collected around the same time. There is a need for better understanding of these two possibly complementary NGS platforms for better integration into clinical practice.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Barata PC, Koshkin VS, Funchain P, et al. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Ann Oncol. 2017. PMID: 28945843. doi:10.1093/annonc/mdx405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。